Deuker et al. (2015) found that the use of inhibitors against the α, δ and γ isoforms of the p110 catalytic subunit of PI3K in conjunction with BRAF inhibitors resulted not only in a greater rate of tumour regression in melanoma cells, but the combination treatment also forestalled the onset of MEK inhibitor resistance [71]. Here, MAP2K7 is linked to melanoma.